Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Global X Cloud Computing ETF (CLOU) Price & Performance

AbbVie IncTrade
Global X Cloud Computing ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Global X Cloud Computing ETF — how do they compare? AbbVie Inc trades at $249.69 (market cap $441.94B), while Global X Cloud Computing ETF trades at $27.75. The key difference: AbbVie Inc pays a 2.77% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.

ABBVCLOU
Market Cap
$441.94B
Sector
HealthSector/Thematic
52-Week High
$263.58$28.09
52-Week Low
$197.38$17.60
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Global X Cloud Computing ETF

CLOU, the Global X Cloud Computing ETF, trades at $27.83, down 0.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides diversified exposure to cloud computing stocks, with top holdings like Snowflake and Datadog showing strong non-AI growth drivers. Recent news highlights long-term growth potential beyond AI hype, supported by customer expansion and resilient subscription revenues.

Outlook remains positive for long-term investors due to structural growth in cloud adoption, though short-term risks include high valuations and sector volatility. Key opportunities lie in business diversification and profitability improvements among holdings, while risks involve competitive pressures and macroeconomic sensitivity affecting tech stocks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Global X Cloud Computing ETF

CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.

Read more on CLOU